Showing posts with label drug design. Show all posts
Showing posts with label drug design. Show all posts

Thursday, 24 October 2013

Why Antibody Lots Differ Significantly


Featured Story
Since antibodies first attained prominence as research reagents in modern biological science labs, researchers have been perplexed as to why one production lot can differ significantly from the next, in terms of performance. Poor antibody performance has caused the loss of countless hours of research, to say nothing of the mental anguish of the researchers themselves. An antigen is a substance that stimulates the production of antibodies.
 http://www.dddmag.com/news/2013/10/why-antibody-lots-differ-significantly?et_cid=3555713&et_rid=523035093&type=cta
fig is Schematic representation of pure and contaminated antibodies carrying histones or histones complexed with DNA. (Source: Biochemistry and Cell Biology)

Sunday, 4 August 2013

Cinnamon's Infection and Diabetes-Fighting Properties Revealed

Cinnamon's Infection and Diabetes-Fighting Properties Revealed
Cinnamon's medicinal potential is as rich and complex as its flavor and aroma, with blood sugar balancing and infection fighting top on the list.
Cinnamon is a familiar spice, but few are aware of just how diverse are its medicinal properties.  TheUS National Library of Medicine houses well over 1300 abstracts on the subject of the various forms of cinnamon's potential health benefits.

Tuesday, 30 July 2013

Garlic an antifungal, garlic can also support your immune system, reduce cholesterol, and help control blood sugar levels.

garlic

Garlic is a proven antifungal . Research studies have shown that garlic is effective against pathogens like Candida. In addition to its use as an antifungal, garlic can support your immune system, reduce cholesterol, and help control blood sugar levels.
You can start taking garlic supplements once you have finished your cleanse and moved on to the strict anti-Candida diet. As always, it is better to take two or three antifungals at once to prevent the Candida from adapting, so you can use garlic in addition to other natural antifungals.

How does Garlic help with Candida overgrowth?

There is a wide range of scientific literature supporting the use of garlic as an antifungal. Much of this research is focused on Candida and similar pathogenic organisms. For example, a 1988 study (see the full text here) found that “the growth of Candida Albicans was found to be markedly inhibited by AGE [aqueous garlic extract]”. According to another article by Huntington College of Health Sciences, “Research has clearly shown that garlic has anticandidal activity, inhibiting both the growth and function of Candida Albicans”.
One of the key compounds in garlic is ajoene, a proven antifungal that has been shown to be effective against many fungal strains. Ajoene is formed from a compound named allicin and an enzyme named allinase. When these two natural compounds come into contact (by chopping the garlic, crushing it or by other means), they form an antibacterial agent named allicin, which then combines to form ajoene. Although this has proven antifungal properties, the exact mechanism by which this happens is not clear. As with other antifungals, scientists suspect that it works by disrupting the cells walls of the Candida yeast cells.
A major advantage of garlic is that it is so easy to include in your treatment plan. Garlic tablets, softgels and oils are widely available, and fresh garlic cloves make a tasty addition to many recipes. You can use garlic as a complement to your other antifungals without having to spend a great deal of money. To get the best results and prevent the Candida yeast from adapting to the treatment, it is best to take two or three antifungals at the same time.

How do you take Garlic?

Garlic products can be found in a number of different forms, in both your supermarket and your health food store. In your supermarket you will find items like fresh garlic cloves, garlic paste, crushed garlic, garlic flakes or garlic powder. Your health food store should stock garlic tablets and garlic oil.
Each type contains different levels of the active ingredients, so make sure to read the ingredients. Here is a basic run-down of the recommended dosage for each type:
  • Garlic cloves: 2 to 4 grams per day of fresh, minced garlic clove
  • Garlic Tablets: 600 to 900 mg daily, freeze-dried garlic standardized to 1.3% alliin or 0.6% allicin
  • Garlic Oil: 0.03 to 0.12 mL three times a day

Who should not take Garlic?

Although a natural remedy, concentrated garlic can still interact with other medicines, so always consult a health professional. Garlic has a blood-thinning property that can be very useful, but can also be dangerous to sufferers of hemophilia or platelet disorders, as well as pregnant women or patients about to undergo surgery.
Side effects from garlic include upset stomach, bloating, bad breath, body odor, and a stinging sensation on the skin from handling too much fresh or dried garlic. Handling garlic may also cause the appearance of skin lesions.
Other side effects that have been reported by those taking garlic supplements include headache, fatigue, loss of appetite, muscle aches, dizziness described as vertigo (namely, the room spinning), and allergies such as an asthmatic reaction or contact dermatitis (skin rash).
Some people may suffer a mild allergic reaction to concentrated garlic. Others may have an upset stomach, body odor, bad breath, headache, loss of appetite or fatigue. It may prompt a skin reaction, such as a stinging in the hands.

Thursday, 25 July 2013

Scripps Research Institute Scientists Find a Potential Cause of Parkinson’s Disease that Points to a New Therapeutic Strategy







 For a high-resolution image see: http://www.scripps.edu/news/press/
images/reed_steve/reed_steve.jpg

LA JOLLA, CA – July 24, 2013 – Biologists at The Scripps Research Institute (TSRI) have made a significant discovery that could lead to a new therapeutic strategy for Parkinson’s disease.
The findings, recently published online ahead of print in the journal Molecular and Cell Biology, focus on an enzyme known as parkin, whose absence causes an early-onset form of Parkinson’s disease. Precisely how the loss of this enzyme leads to the deaths of neurons has been unclear. But the TSRI researchers showed that parkin’s loss sharply reduces the level of another protein that normally helps protect neurons from stress.
 http://www.scripps.edu/news/press/2013/20130724reed.html

Monday, 22 July 2013

Cancer drug tested in pet dogs is now bound for human trials

File:PAC-1.svg
PAC 1
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

If PAC-1 (pack one) makes it through the U.S. Food and Drug Administration’s Investigational New Drug review, the first human (Phase I) clinical trial of the drug will begin in mid-2014. The investor, who wishes to remain anonymous, has an option to invest another $2 million to take the drug into human trials. The clinical work will be conducted at the University of Illinois Cancer Center in Chicago.

http://news.illinois.edu/news/13/0717cancer_drug_PaulHergenrother_TimFan.html






Photo by
L. Brian Stauffer

University of Illinois chemistry professor Paul Hergenrother, left, and veterinary clinical medicine professor Tim Fan led a study of an anti-cancer compound in pet dogs that is now headed for human clinical trials.
PAC-1 (first procaspase activating compound) is a synthesized chemical compound that selectively induces apoptosis, or cell suicide, in cancerous cells. PAC-1 has shown good results in mouse models and is being further evaluated for use in humans. In 2010 a published study showed PAC-1 to be safe to research dogs, and a second study published later that same year reported that a PAC-1 derivative (called S-PAC-1) was well tolerated in a small Phase I Clinical Trial of pet dogs with lymphoma. Even at low doses of S-PAC-1, tumors regressed in 1/6 dogs, and the disease was stabilized (no additional tumor growth) in 3/6 dogs

Friday, 19 July 2013